Therapeutic monoclonal antibodies for COVID-19 management: an update
Top Cited Papers
- 29 May 2022
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Biological Therapy
- Vol. 22 (6), 763-780
- https://doi.org/10.1080/14712598.2022.2078160
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected more than 529 million people, and today the world is facing different mutant strains of the virus, leading to increased morbidity rates, fatality rates, and surfacing re-infections. Various therapies, such as prophylactic treatments, repurposed drug treatments, convalescent plasma, and polyclonal antibody therapy have been developed to help combat the coronavirus disease 2019 (COVID-19). This review article provides insights into the basic aspects of monoclonal antibodies (mAbs) for the therapy of COVID-19, as well as its advancement in terms of clinical trial and current approval status. Monoclonal antibodies represents the most effective and viable therapy and/or prophylaxis option against COVID-19, and have shown a reduction of the viral load, as well as lowering hospitalizations and death rates. In different countries, various mAbs are undergoing different phases of clinical trials, with a few of them having entered phases III and IV. Due to the soaring number of cases worldwide, the FDA has given emergency approval for the mAb combinations bamlanivimab with etesevimab and casirivimab with imdevimab.Keywords
Funding Information
- No funding
This publication has 144 references indexed in Scilit:
- Type 2 Diabetes and its Impact on the Immune SystemCurrent Diabetes Reviews, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Nsp3 of coronaviruses: Structures and functions of a large multi-domain proteinAntiviral Research, 2017
- Signaling by Antibodies: Recent ProgressAnnual Review of Immunology, 2017
- Drug repurposing from the perspective of pharmaceutical companiesBritish Journal of Pharmacology, 2017
- Design of Potential RNAi (miRNA and siRNA) Molecules for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Gene Silencing by Computational MethodInterdisciplinary Sciences: Computational Life Sciences, 2015
- Interspecies transmission and emergence of novel viruses: lessons from bats and birdsTrends in Microbiology, 2013
- Immunopathogenesis of coronavirus infections: implications for SARSNature Reviews Immunology, 2005
- From the FedsJournal of Emergency Nursing, 2000